Related Experiment Video

Updated: Aug 30, 2026

High-throughput Screening of Chemical Compounds to Elucidate Their Effects on Bacterial Persistence
07:25

High-throughput Screening of Chemical Compounds to Elucidate Their Effects on Bacterial Persistence

Published on: February 23, 2021

Ofloxacin in multidrug resistant tuberculosis

P P Walwaikar1, V K Morye, A S Gawde

  • 1JB Chemicals & Pharmaceuticals Limited, Mumbai 400025.

Journal of the Indian Medical Association
|November 8, 2003
PubMed

Insights

Tuberculosis (TB) treatment requires new drugs due to rising multidrug-resistant TB (MDR-TB). Ofloxacin shows promise as an effective agent for treating MDR-TB, especially when standard treatments fail.

Area of Science:

  • * Infectious Diseases
  • * Pharmacology
  • * Microbiology

Background:

  • * Tuberculosis (TB) remains a leading infectious cause of death globally.
  • * Current six-month treatment regimens face challenges from multidrug-resistant TB (MDR-TB) and HIV co-infection.
  • * There is a critical need for novel, non-toxic antitubercular agents.

Purpose of the Study:

  • * To evaluate ofloxacin as a potential agent for treating multidrug-resistant tuberculosis (MDR-TB).
  • * To assess the efficacy of fluoroquinolones in the context of challenging TB treatment scenarios.

Main Methods:

  • * Review of in-vitro and in-vivo clinical studies.
  • * Analysis of World Health Organization (WHO) recommendations for MDR-TB treatment.

Main Results:

  • * Ofloxacin has been identified as a promising agent in both laboratory and clinical settings for MDR-TB.
  • * WHO advocates for ofloxacin in specific MDR-TB treatment situations, including empirical therapy and when resistance is confirmed.

Conclusions:

  • * Ofloxacin represents a valuable therapeutic option for managing multidrug-resistant tuberculosis (MDR-TB).
  • * Its use is particularly recommended when susceptibility results are pending or when resistance to first-line drugs is evident.

More Related Videos

Assay Development for High-Throughput Drug Screening Against Mycobacteria07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
Antibiotic Selection01:45

Antibiotic Selection

Researchers use antibiotic resistance genes to identify bacteria that possess a plasmid containing their gene of interest. Antibiotic resistance naturally occurs when a spontaneous DNA mutation creates changes in bacterial genes that eliminate antibiotic activity. Bacteria can share these new resistance genes with their offspring and other bacteria. The overuse and misuse of antibiotics have created a public health crisis, as resistant and multi-resistant bacteria continue to develop.Antibiotic...